Valuation: MannKind Corporation

Market Cap 1.03B 916M 851M 774M 1.46B 97.15B 1.48B 10.22B 4B 50.69B 3.85B 3.77B 162B P/E 2026 *
-17.4x
P/E 2027 * 1,276x
Enterprise Value 1.03B 916M 851M 774M 1.46B 97.15B 1.48B 10.22B 4B 50.69B 3.85B 3.77B 162B EV / Sales 2026 *
2.31x
EV / Sales 2027 * 2.03x
Free-Float
98.53%
Yield 2026 *
-
Yield 2027 * -
1 day+5.63%
1 week-6.73%
Current month-18.21%
1 month-10.39%
3 months-22.00%
6 months+15.16%
Current year-43.74%
1 week 2.9
Extreme 2.895
3.27
1 month 2.9
Extreme 2.895
4.22
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 24/05/2017
Director of Finance/CFO 50 21/04/2024
Chief Tech/Sci/R&D Officer - 28/09/2025
Director TitleAgeSince
Director/Board Member 82 30/09/2003
Director/Board Member 82 30/11/2003
Chairman 69 08/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
25/09/26 Sell

Director

-39,051 0.0121%
10/09/26 Sell

Director

-33,558 0.0104%
07/08/26 Sell

Director

-39,051 0.0122%
Change 5-day change 1-year change 3-year change Capi.($)
+5.63%-6.73%-39.01%-20.05% 1.03B
+0.21%-4.63%+55.34%+71.32% 68.98B
+1.66%+7.51%+8.12%+60.04% 53.15B
+3.14%+7.17%+12.48%+44.42% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
+2.47%-7.45%+35.95%+1.71% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +2.38%+0.73%+40.47%+86.76% 38.07B
Weighted average by Cap. +1.96%+2.31%+51.26%+103.37%

Financials

2026 *2027 *
Net sales 445M 397M 369M 336M 631M 42.12B 643M 4.43B 1.73B 21.98B 1.67B 1.63B 70.32B 506M 451M 419M 382M 718M 47.89B 731M 5.04B 1.97B 24.99B 1.9B 1.86B 79.96B
Net income -57.57M -51.38M -47.76M -43.44M -81.73M -5.45B -83.2M -574M -224M -2.84B -216M -211M -9.1B 1.05M 940K 874K 795K 1.5M 99.76M 1.52M 10.5M 4.11M 52.05M 3.95M 3.87M 167M
Net Debt - -
Projected Income Statement - Annual - MannKind Corporation
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
15/10/26 US$3.190 +5.63% 3,756,600
14/10/26 US$3.020 -0.98% 7,938,733
13/10/26 US$3.050 -2.56% 4,394,241
12/10/26 US$3.130 -4.86% 3,958,086
09/10/26 US$3.290 -3.80% 4,549,647
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MannKind Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.190USD
Average target price
7.844USD
Spread / Average Target
+145.89%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MannKind Corporation
  1. Stock Market
  2. Stocks
  3. MNKD Stock